Indian Generics Face Lower Third-Quarter Income Without New Launches
This article was originally published in PharmAsia News
Increasing competition and pressures in the United States and Europe to hold down the price of generic drugs threaten to reduce the income reports of Indian pharmaceuticals for the third quarter of 2007. The reduction also is expected in part because of lower income for authorized generics and the effects of a strong rupee. A Sarabjit Kour Nangra research vice president noted no new products were launched in India during the third quarter. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.